公开(公告)号：WO2016008560A1

公开(公告)日：2016-01-21

申请号：PCT/EP2015/001239

申请日：2015-06-19

Applicant: PHARMATHEN S.A.

Inventor： KARAVAS, Evangelos ,  KOUTRIS, Efthymios ,  SAMARA, Vasiliki ,  KOUTRI, Ioanna ,  KALASKANI, Anastasia ,  KALANTZI, Lida ,  KAKOURIS, Andreas ,  DIAKIDOU, Amalia ,  GOTZAMANIS, George ,  GEORGOUSIS, Zaharias ,  FOUSTERIS, Manolis

IPC: A61K9/14

CPC classification number: A61K31/522 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/141 ,  A61K9/145 ,  A61K9/1629 ,  A61K9/1652

Abstract: The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.

Abstract translation: 本发明涉及一种作为口服给药悬浮液重建用的儿科粉末，其包含治疗有效量的特定比例的离子交换树脂与治疗有效量的抗病毒剂或其药学上可接受的盐或其衍生物，特别是伐昔洛韦复合物，以获得 一个可口和儿童友好的产品。 它还涉及其制备方法。

公开(公告)号：WO2015095772A2

公开(公告)日：2015-06-25

申请号：PCT/US2014/071623

申请日：2014-12-19

Applicant: EMORY UNIVERSITY ,  GEORGIA TECH RESEARCH CORPORATION

Inventor： PRAUSNITZ, Mark R. ,  KIM, Yoo Chun ,  EDELHAUSER, Henry F.

IPC: A61K9/00

CPC classification number: A61K9/0051 ,  A61K9/0021 ,  A61K9/10 ,  A61K9/107 ,  A61K9/1611 ,  A61K9/1629 ,  A61K31/137 ,  A61K31/498 ,  A61K31/5575 ,  A61K39/395 ,  A61K39/3955 ,  A61K47/36 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61M37/0015 ,  A61M2037/0053 ,  B23K26/0093 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/76

Abstract: Formulations, systems, and methods of administration are provided for preferential targeted delivery of drug to ocular tissue. In embodiments, the formulation may include a non-Newtonian fluid that facilitates targeted localization or preferential spreading of the fluid formulation in the ocular tissue. The fluid formulation may be administered to an eye of a patient by inserting a microneedle into the eye at an insertion site, and infusing a volume of a fluid formulation through the microneedle into the suprachoroidal space of the eye at the insertion site over a first period. During the first period, the fluid formulation may be distributed over a first region which is less than about 10% of the suprachoroidal space, and during the second period subsequent to the first period the drug formulation may be distributed over a second region which is greater than about 20% of the suprachoroidal space.

Abstract translation: 提供给药的制剂，系统和方法用于将药物优先靶向递送至眼组织。 在实施方案中，所述制剂可以包括促进所述流体制剂在所述眼组织中的定向定位或优先扩散的非牛顿流体。 可以通过在插入位置处将微针插入眼睛中并且在插入位置处在第一时间段内将一定体积的流体制剂通过微针注入到眼睛的脉络膜上腔中来将流体制剂施用于患者的眼睛 。 在第一阶段期间，流体制剂可以分布在少于脉络膜上腔的约10％的第一区域上，并且在第一阶段之后的第二阶段期间，药物制剂可以分布在更大的第二区域 超过脉络膜上腔的约20％。

公开(公告)号：WO2015082998A1

公开(公告)日：2015-06-11

申请号：PCT/IB2014/003029

申请日：2014-12-04

Applicant: HOVIONE SCIENTIA LIMITED

Inventor： SMITH, Courtney, Rouse ,  TEMTEM, Marcio ,  WINTERS, Conrad

IPC: A61K9/00 ,  A61K9/16 ,  A61K49/04

CPC classification number: A61K9/146 ,  A61K9/1629 ,  A61K9/1635 ,  A61K9/1652 ,  A61K49/048 ,  A61K49/0495

Abstract: The disclosure provides oral solid particle formulations comprising of an iodinated imaging agent and at least one taste masking agent showing improved bioadhesive properties, and are also useful for imaging of the gastrointestinal tract.

Abstract translation: 本公开提供了包含碘化显像剂和显示出改进的生物粘合性质的至少一种掩味剂的口服固体颗粒制剂，并且还可用于胃肠道成像。

公开(公告)号：WO2012051426A3

公开(公告)日：2013-10-17

申请号：PCT/US2011056166

申请日：2011-10-13

Applicant: GLAXO GROUP LTD ,  HONG JOHN N ,  VAN OORT MICHIEL M

Inventor： HONG JOHN N ,  VAN OORT MICHIEL M

IPC: A61K9/14

CPC classification number: A61K31/56 ,  A61K9/0075 ,  A61K9/008 ,  A61K9/145 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1629 ,  A61K9/1688 ,  A61K9/513 ,  A61K31/137 ,  A61K31/4709 ,  A61K31/57

Abstract: A method of making aggregate particles suitable for a pharmaceutical aerosol composition that includes (a) forming a dispersion of nanoparticulate drug particles and/or excipient nanoparticles in a non-aqueous liquid, wherein said particles have a solubility of less than 10 mg/ml in said liquid dispersing media, wherein the nanoparticulate drug particles have a preselected crystalline form; (b) spray- drying the dispersion of nanoparticulate drug particles and/or nanoparticulate excipient particles to generate aggregate particles comprising nanoparticulate drug particles and/or nanoparticulate excipient particles, wherein the drug and/or excipient nanoparticles have maintained their preselected crystalline form, and wherein the aggregate particles have a mass median diameter of less than or equal to about 100 microns and wherein when the nanoparticles dispersed in said dispersion do not comprise excipient. the aggregate particles is substantially free of a homogenizing surfactant. When the nanoparticles in said dispersion do not comprise excipient, the non-aqueous liquid has no suspension surfactant.

Abstract translation: 制备适合于药物气溶胶组合物的骨料颗粒的方法，其包括（a）在非水性液体中形成纳米颗粒状药物颗粒和/或赋形剂纳米颗粒的分散体，其中所述颗粒的溶解度小于10mg / ml 所述液体分散介质，其中所述纳米颗粒药物颗粒具有预选的结晶形式; （b）喷雾干燥纳米颗粒药物颗粒和/或纳米颗粒赋形剂颗粒的分散体以产生包含纳米颗粒药物颗粒和/或纳米颗粒赋形剂颗粒的聚集颗粒，其中所述药物和/或赋形剂纳米颗粒保持其预选的结晶形式，并且其中 聚集颗粒具有小于或等于约100微米的质量中值直径，并且其中当分散在所述分散体中的纳米颗粒不包含赋形剂时。 聚集体颗粒基本上不含均化表面活性剂。 当所述分散体中的纳米颗粒不包含赋形剂时，非水性液体不含悬浮表面活性剂。

公开(公告)号：WO2009152190A1

公开(公告)日：2009-12-17

申请号：PCT/US2009/046805

申请日：2009-06-09

Applicant: VIVUS, INC. ,  NAJARIAN, Thomas ,  TAM, Peter, Y. ,  WILSON, Leland, F.

Inventor： NAJARIAN, Thomas ,  TAM, Peter, Y. ,  WILSON, Leland, F.

IPC: A61K31/35 ,  A61K31/137 ,  A61P3/04

CPC classification number: A61K31/357 ,  A61K9/1623 ,  A61K9/1629 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/4866 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/35 ,  A61K31/7048 ,  A61K47/38 ,  A61K2300/00

Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Abstract translation: 本发明涉及新的托吡酯组合物以及用于减轻体重的方法，例如用于治疗肥胖症和相关病症，包括与肥胖本身相关的和/或由肥胖本身引起的疾病。 本发明的特征在于适于在治疗肥胖症和相关病症中施用托吡酯和任选的拟交感神经药物如苯丁胺或安非他酮的升级给药方案。

公开(公告)号：WO2009109836A1

公开(公告)日：2009-09-11

申请号：PCT/IB2009/000413

申请日：2009-03-04

Applicant: LABORATORIOS SENOSIAN S.A. DE C.V. ,  SENOSIAN AGUILAR, Juan Aurelio ,  GARCIA SALGADO LOPEZ, E.Raúl ,  ARZOLA PANIAGUA, M. Angélica ,  BARRANCO HARNÁNDEZ, Gustavo

Inventor： SENOSIAN AGUILAR, Juan Aurelio ,  GARCIA SALGADO LOPEZ, E.Raúl ,  ARZOLA PANIAGUA, M. Angélica ,  BARRANCO HARNÁNDEZ, Gustavo

IPC: A61K31/405 ,  A61K31/51 ,  A61K31/4415 ,  A61K31/714 ,  A61P29/00

CPC classification number: A61K9/4866 ,  A61K9/1629 ,  A61K9/1676 ,  A61K9/209 ,  A61K9/5078 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4415 ,  A61K31/51 ,  A61K31/714 ,  C07D487/04 ,  A61K2300/00

Abstract: La presente invención se refiere a una composición farmacéutica oral sólida que comprende la combinación de ketorolaco y Complejo B, compuesto entre otros de tiamina, piridoxina y cianocobalamina (vitaminas B1, B6 y B12, respectivamente) y/o sus sales farmacéuticamente aceptables, adicionalmente, vehículos y/o excipientes farmacéuticamente aceptables; el proceso de fabricación de la composición y el uso de dicha composición con actividad terapéutica sinérgica, indicada para el tratamiento de dolor de moderado a severo o neuralgias de diversas localización.

Abstract translation: 本发明涉及一种固体口服药物组合物，其结合酮多酸和B复合物，其特别包括硫胺素，吡哆醇和氰钴胺素（分别为维生素B1，B6和B12）和/或其药学上可接受的盐，以及药学上可接受的赋形剂和/ 或车辆。 本发明还涉及用于生产组合物的方法和所述具有协同治疗活性的组合物的用途，其指示用于治疗不同位置的中度至重度疼痛或神经痛。

公开(公告)号：WO2006093838A2

公开(公告)日：2006-09-08

申请号：PCT/US2006/006670

申请日：2006-02-24

Applicant: PFAB LP ,  TENGLER, Mark ,  TASKEY, Paul ,  LOCKHART, Daniel ,  MCMAHEN, Russell Lee

Inventor： TENGLER, Mark ,  TASKEY, Paul ,  LOCKHART, Daniel ,  MCMAHEN, Russell Lee

CPC classification number: A61K9/5078 ,  A61K9/0095 ,  A61K9/10 ,  A61K9/1629 ,  A61K36/02 ,  A61K36/06 ,  A61K45/06 ,  Y02A50/402 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/491 ,  A61K2300/00

Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.

Abstract translation: 本发明包括通过混合一种或多种包含一种或多种活性剂的控制释放微珠，制备密度为或更小的致密的触变溶液，将活性剂控制释放在储存稳定的液体制剂中的组合物和方法 约在一个或多个微珠的密度，其包含触变剂，水和一种或多种防腐剂，在减少气泡形成和混合微珠和触变溶液的混合器中，其缺少刮刮桨。

公开(公告)号：WO2006017195A1

公开(公告)日：2006-02-16

申请号：PCT/US2005/024353

申请日：2005-07-08

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD. ,  MARGALIT, Rimona ,  PEER, Dan

Inventor： MARGALIT, Rimona ,  PEER, Dan

IPC: A61K9/10

CPC classification number: A61K9/5052 ,  A61K9/1629 ,  A61K9/1658 ,  A61K9/5089 ,  A61K31/14 ,  A61K31/165 ,  A61K31/196 ,  A61K31/351 ,  A61K31/407 ,  A61K31/704 ,  A61K31/7088 ,  A61K31/711 ,  A61K38/212 ,  A61K38/28 ,  A61K38/385 ,  A61K45/06 ,  A61K47/545 ,  A61K48/0008 ,  A61K49/0002 ,  A61K49/0043 ,  A61K51/08 ,  A61K51/1265

Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.

Abstract translation: 通过将糖蛋白（通常为胶原）与至少一种脂质共价连接来制备脂质化的微粒或大颗粒。 糖蛋白中的氨基与脂质中的伯胺结合。 这些颗粒可用于包封活性成分，如药物。

公开(公告)号：WO2013058721A1

公开(公告)日：2013-04-25

申请号：PCT/TR2012/000172

申请日：2012-10-12

Applicant: BILGIC, Mahmut

Inventor： BILGIC, Mahmut

IPC: A61K9/16 ,  A61K31/495

CPC classification number: A61K9/1694 ,  A61K9/0007 ,  A61K9/1629 ,  A61K9/2022 ,  A61K31/495 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical granules having maximum 1% of moisture content by weight and production method thereof.

Abstract translation: 本发明涉及具有最大1重量％水分含量的药物颗粒及其制备方法。

公开(公告)号：WO2013015685A1

公开(公告)日：2013-01-31

申请号：PCT/NL2012/050529

申请日：2012-07-23

Applicant: INNOCORE TECHNOLOGIES B.V. ,  STEENDAM, Rob ,  FLIPSEN, Theodorus Adrianus Cornelius ,  HIEMSTRA, Christine ,  ZUIDEMA, Johan

Inventor： STEENDAM, Rob ,  FLIPSEN, Theodorus Adrianus Cornelius ,  HIEMSTRA, Christine ,  ZUIDEMA, Johan

IPC: C08G81/00 ,  A61K9/16 ,  C08L87/00

CPC classification number: A61K9/4816 ,  A61K9/08 ,  A61K9/1629 ,  A61K9/1641 ,  A61K9/5021 ,  A61K9/5031 ,  A61K9/7007 ,  C08G81/00 ,  C08L87/005

Abstract: This invention is directed to a biodegradable, semi-crystalline, phase separated thermoplastic multi-block copolymer, a process for preparing said multi-block copolymer, a composition for the delivery of at least one biological active compound, and to a method for delivering a biologically active compound to a subject in need thereof. A multi-block copolymer of the invention is characterised in that: a) it comprises at least one hydrolysable pre-polymer (A) segment and at least one hydrolysable pre-polymer (B) segment, b) said multi-block copolymer having a T g of 37 °C or less and a Tm of 110-250 °C under physiological conditions; c) the segments are linked by a multifunctional chain-extender; d) the segments are randomly distributed over the polymer chain; e) at least part of the pre-polymer (A) segment is derived from a water-soluble polymer.

Abstract translation: 本发明涉及可生物降解的半结晶相分离的热塑性多嵌段共聚物，制备所述多嵌段共聚物的方法，用于递送至少一种生物活性化合物的组合物，以及用于递送 生物活性化合物。 本发明的多嵌段共聚物的特征在于：a）其包含至少一种可水解预聚物（A）链段和至少一种可水解预聚物（B）链段，b）所述多嵌段共聚物具有 Tg在37℃以下，在生理条件下Tm为110〜250℃。 c）片段由多功能增链剂连接; d）片段随机分布在聚合物链上; e）至少部分预聚物（A）链段衍生自水溶性聚合物。